Organization · Venture Capital
415 Capital
415 Capital is a venture capital firm based in Munich, Germany, specializing in breakthrough medical innovations. With over 30 years of experience, they focus on addressing unmet patient needs in chronic diseases, particularly in cardio and neurovascular disorders.
Overview
What 415 Capital does
What 415 Capital is
415 Capital is a venture capital firm based in Munich, Germany, specializing in breakthrough medical innovations. With over 30 years of experience, they focus on addressing unmet patient needs in chronic diseases, particularly in cardio and neurovascular disorders.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Structured capabilities
- Funder
- Last reviewed
- March 18, 2026
Official channels
Find 415 Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
415 Capital as a funder
Investment thesis
415 Capital is dedicated to investing in breakthrough medical innovations that address significant unmet patient needs, particularly in chronic diseases related to cardio and neurovascular disorders.
Focus narrative
415 Capital invests in medical technologies at clinical through commercial stages, targeting sectors such as Structural Heart Disease, Heart Failure, Aortic & Peripheral Vascular Disease, Neurovascular Disease, Hypertension, Electrophysiology, Neuromodulation for Chronic Diseases, Medical Imaging, Medical Robotics, and Patient Monitoring. The firm does not invest in biotech/pharma, healthcare services, or wellness products.
Value beyond capital
415 Capital adds value to its portfolio companies by leveraging its extensive expertise in medical technologies and its network within the healthcare industry to support clinical development and commercialization efforts.
Terms and economics
- Typical check
- $5,000,000–$15,000,000
Focus and fit
- Stages
- Series A · Series B · Growth Equity
- Sectors
- Healthcare · Biotech · Medical Devices
- Regions
- EuropeNorth America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded notable exits
- Vesper Medical, CoRRect Medical, Intact Vascular, and Mitralign
Portfolio context
Notable portfolio companies include Endovascular Engineering, developing a next-generation clot removal technology platform; Laza Medical, providing AI-powered cardiovascular robotics; Supira Medical, with a low-profile percutaneous ventricular assist device; R 3 Vascular, focusing on bioresorbable vascular scaffold technology; CorFlow Therapeutics, for microvascular obstruction therapy; Cardiac Success, with a transcatheter device for heart failure; Hilo, for blood pressure control; Distalmotion, with surgical robotics; and TRiCares, for transcatheter valve replacement.
Common questions
What to know about 415 Capital
Upseed classifies 415 Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 18, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.